Lajos Raduly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4275672/publications.pdf

Version: 2024-02-01

471061 414034 1,469 34 17 32 citations h-index g-index papers 38 38 38 2444 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	MicroRNA Dysregulation in Prostate Cancer. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 177-193.	0.4	4
2	Dysregulation of miR-21-5p, miR-93-5p, miR-200c-3p and miR-205-5p in Oral Squamous Cell Carcinoma: A Potential Biomarkers Panel?. Current Issues in Molecular Biology, 2022, 44, 1754-1767.	1.0	8
3	Targeting Cell Death Mechanism Specifically in Triple Negative Breast Cancer Cell Lines. International Journal of Molecular Sciences, 2022, 23, 4784.	1.8	1
4	Comprehensive Analysis of the Expression of Key Genes Related to Hippo Signaling and Their Prognosis Impact in Ovarian Cancer. Diagnostics, 2021, 11, 344.	1.3	3
5	Hsa-miR-125b Therapeutic Role in Colon Cancer Is Dependent on the Mutation Status of the TP53 Gene. Pharmaceutics, 2021, 13, 664.	2.0	2
6	Epithelial–Mesenchymal Transition Gene Signature Related to Prognostic in Colon Adenocarcinoma. Journal of Personalized Medicine, 2021, 11, 476.	1,1	9
7	Cannabidiol and Vitamin D3 Impact on Osteogenic Differentiation of Human Dental Mesenchymal Stem Cells. Medicina (Lithuania), 2020, 56, 607.	0.8	18
8	New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 241.	3.5	17
9	Cancer-Associated Stemness and Epithelial-to-Mesenchymal Transition Signatures Related to Breast Invasive Carcinoma Prognostic. Cancers, 2020, 12, 3053.	1.7	14
10	New perspectives in triple-negative breast cancer therapy based on treatments with TGF \hat{I}^21 siRNA and doxorubicin. Molecular and Cellular Biochemistry, 2020, 475, 285-299.	1.4	15
11	Spontaneous and Induced Animal Models for Cancer Research. Diagnostics, 2020, 10, 660.	1.3	42
12	Plasma and Tissue Specific miRNA Expression Pattern and Functional Analysis Associated to Colorectal Cancer Patients. Cancers, 2020, 12, 843.	1.7	40
13	New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells. Cellular Physiology and Biochemistry, 2020, 54, 648-664.	1.1	19
14	Mir-23a and mir-181b serum levels in irritable bowel syndrome and colorectal cancer – A pilot study. Bosnian Journal of Basic Medical Sciences, 2020, 20, 254-261.	0.6	5
15	Circulating microRNA-194 and microRNA-1228 Could Predict Colon Cancer Proliferation via Phospho S6 Modulation. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 361-367.	0.5	O
16	<p>SERS-based differential diagnosis between multiple solid malignancies: breast, colorectal, lung, ovarian and oral cancer</p> . International Journal of Nanomedicine, 2019, Volume 14, 6165-6178.	3.3	62
17	Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression. Journal of Experimental and Clinical Cancer Research, 2019, 38, 433.	3.5	38
18	Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms. Molecular Aspects of Medicine, 2019, 70, 90-105.	2.7	31

#	Article	IF	CITATIONS
19	A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers, 2019, 11, 1618.	1.7	517
20	The extensive role of miR-155 in malignant and non-malignant diseases. Molecular Aspects of Medicine, 2019, 70, 33-56.	2.7	33
21	The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics― International Journal of Molecular Sciences, 2019, 20, 2576.	1.8	24
22	Isolation and Characterization of a Fetal-Maternal Microchimeric Stem Cell Population in Maternal Hair Follicles Long after Parturition. Stem Cell Reviews and Reports, 2019, 15, 519-529.	5.6	12
23	Inhibitory Effect of CAPE and Kaempferol in Colon Cancer Cell Lines—Possible Implications in New Therapeutic Strategies. International Journal of Molecular Sciences, 2019, 20, 1199.	1.8	44
24	CRISPR-based RNA editing: diagnostic applications and therapeutic options. Expert Review of Molecular Diagnostics, 2019, 19, 83-88.	1.5	15
25	miRâ€181a/b therapy in lung cancer: reality or myth?. Molecular Oncology, 2019, 13, 9-25.	2.1	34
26	The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression. Cell Death and Disease, 2018, 9, 66.	2.7	78
27	Securidaca –saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells. Cancer Management and Research, 2018, Volume 10, 5709-5724.	0.9	17
28	Aberrant miRNAs expressed in HER-2 negative breast cancers patient. Journal of Experimental and Clinical Cancer Research, 2018, 37, 257.	3.5	46
29	Premature senescence activation in DLD‑1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death. Experimental and Therapeutic Medicine, 2018, 16, 1241-1249.	0.8	8
30	Overview upon miR-21 in lung cancer: focus on NSCLC. Cellular and Molecular Life Sciences, 2018, 75, 3539-3551.	2.4	176
31	Implications of dietary ï‰â€'3 and ï‰â€'6 polyunsaturated fatty acids in breast cancer (Review). Experimental an Therapeutic Medicine, 2017, 15, 1167-1176.	d _{0.8}	44
32	Evaluation of cellular and molecular impact of zearalenone and Escherichia coli co-exposure on IPEC-1 cells using microarray technology. BMC Genomics, 2016, 17, 576.	1.2	19
33	Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers. OncoTargets and Therapy, 2015, 8, 2053.	1.0	70
34	C , O $\hat{a} \in \mathbb{C}$ helated organotin(IV) derivatives as potential anticancer agents: Synthesis, characterization, and cytotoxic activity. Applied Organometallic Chemistry, 0, , .	1.7	3